These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 16839270)
41. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy. Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273 [TBL] [Abstract][Full Text] [Related]
42. Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. Hangalapura BN; Oosterhoff D; Gupta T; de Groot J; Wijnands PG; van Beusechem VW; den Haan J; Tüting T; van den Eertwegh AJ; Curiel DT; Scheper RJ; de Gruijl TD Vaccine; 2011 Mar; 29(12):2313-21. PubMed ID: 21272606 [TBL] [Abstract][Full Text] [Related]
43. [Gene transfer of murine Flt3 ligand mediated by adenoviral vector efficiently induces growth inhibition of murine liver cancer]. Yang Q; Yang G; Wei L; Jia F; Wu M; Guo Y Zhonghua Yi Xue Za Zhi; 2002 Jun; 82(11):775-9. PubMed ID: 12126551 [TBL] [Abstract][Full Text] [Related]
44. Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. Ribas A; Butterfield LH; Hu B; Dissette VB; Meng WS; Koh A; Andrews KJ; Lee M; Amar SN; Glaspy JA; McBride WH; Economou JS Cancer Res; 2000 Apr; 60(8):2218-24. PubMed ID: 10786687 [TBL] [Abstract][Full Text] [Related]
45. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Pullarkat V; Lee PP; Scotland R; Rubio V; Groshen S; Gee C; Lau R; Snively J; Sian S; Woulfe SL; Wolfe RA; Weber JS Clin Cancer Res; 2003 Apr; 9(4):1301-12. PubMed ID: 12684398 [TBL] [Abstract][Full Text] [Related]
46. [Xenogeneic melanoma-related antigen elicits anti-tumor immune response, companied by autoimmune injury]. Tan XH; Wan YH Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(23):1596-600. PubMed ID: 16185524 [TBL] [Abstract][Full Text] [Related]
47. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. Perricone MA; Smith KA; Claussen KA; Plog MS; Hempel DM; Roberts BL; St George JA; Kaplan JM J Immunother; 2004; 27(4):273-81. PubMed ID: 15235388 [TBL] [Abstract][Full Text] [Related]
48. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. Schreurs MW; de Boer AJ; Figdor CG; Adema GJ Cancer Res; 1998 Jun; 58(12):2509-14. PubMed ID: 9635569 [TBL] [Abstract][Full Text] [Related]
49. Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor. Rakhmilevich AL; Imboden M; Hao Z; Macklin MD; Roberts T; Wright KM; Albertini MR; Yang NS; Sondel PM Clin Cancer Res; 2001 Apr; 7(4):952-61. PubMed ID: 11309346 [TBL] [Abstract][Full Text] [Related]
50. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100. Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635 [TBL] [Abstract][Full Text] [Related]
51. Safety of interleukin-12 gene therapy against cancer: a murine biodistribution and toxicity study. Imboden M; Shi F; Pugh TD; Freud AG; Thom NJ; Hank JA; Hao Z; Staelin ST; Sondel PM; Mahvi DM Hum Gene Ther; 2003 Jul; 14(11):1037-48. PubMed ID: 12885344 [TBL] [Abstract][Full Text] [Related]
52. Combination of MIDGE-Th1 DNA vaccines with the cationic lipid SAINT-18: studies on formulation, biodistribution and vector clearance. Endmann A; Oswald D; Riede O; Talman EG; Vos RE; Schroff M; Kleuss C; Ruiters MH; Juhls C Vaccine; 2014 Jun; 32(27):3460-7. PubMed ID: 24681271 [TBL] [Abstract][Full Text] [Related]
53. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214 [TBL] [Abstract][Full Text] [Related]
54. Segregation of mechanisms for cytotoxic T lymphocyte killing between lungs and regional lymph nodes subsequent to intratracheal delivery of adenovirus 2 vector. Wang X; Hillemeyer P; Pascual DW Viral Immunol; 2003; 16(4):525-39. PubMed ID: 14733739 [TBL] [Abstract][Full Text] [Related]
55. Dynamic distribution and expression in vivo of the human interferon gamma gene delivered by adenoviral vector. Wu J; Xiao X; Jia H; Chen J; Zhu Y; Zhao P; Lin H; Huang W BMC Cancer; 2009 Feb; 9():55. PubMed ID: 19216804 [TBL] [Abstract][Full Text] [Related]